Remdesivir: WHO advises against the drug of hope against the crown – health



[ad_1]

It used to be considered one of the beacons of hope in the fight against the serious diseases of Covid 19 – but now the World Health Organization (WHO) advises against using the drug Remdesivir!

After careful consideration, a WHO expert panel concluded that the drug “does not have a significant influence on mortality or other major effects on patients, such as the need for artificial ventilation or time to recovery,” he said. wrote the British Medical Journal (BMJ) in an article published Friday.

It is also not yet ruled out that the drug may also cause harm. In addition, there are costs for use: a treatment for five days costs 1976 euros, according to the BMJ.

Remdesivir was originally developed by the US pharmaceutical company Gilead to fight the Ebola virus. After the outbreak of the global pandemic, for a while it was considered a beacon of hope in the fight against Covid-19.

In July, it was the first drug in Europe to receive conditional approval for the specific treatment of certain patients. More recently, however, tests have suggested that the drug’s benefit is minimal at best.

The findings emerged from a WHO-coordinated study with thousands of patients in nearly 500 clinics in more than 30 countries.

The manufacturer Gilead, on the other hand, refers in a recent statement to “proven clinical benefits in hospitalized COVID-19 patients.” The benefits include “notably a significantly faster recovery time” so that hospitals are less busy.

The first results of the study, published in October, showed that Covid-19 patients treated with Remdesivir recovered on average about five days faster (10 instead of 15 days) than other sufferers.

In Germany, the drug will initially continue to be used for the treatment of coronary patients. A spokesperson for the Ministry of Health announced that it would await a reassessment at the community level. Remdesivir is used only in very specific cases.

.

[ad_2]
Source link